Loading...

Danielle Schlosser, PhD

TitleAssistant Professor
SchoolUCSF School of Medicine
DepartmentPsychiatry
Address401 Parnassus Ave.
San Francisco CA 94143
Phone415-476-8721
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    NIH/NIMH 2013  - 2018Career Development Award (K23 MH097795)
    NIH/NIMH2013  - 2016Clinical Trial Planning Award (R34 MH100399)
    UCSF, CTSI2014  - 2015Digital Health Research Award
    UCSF, CTSI2013  - 2014Catalyst Award in Digital Health
    UCSF, CTSI2012  - 2013Mobile Health Research Award

    Collapse Overview 
    Collapse Overview
    Dr. Schlosser currently holds the positions of Assistant Professor in the Department of Psychiatry at the University of California, San Francisco, Director of the Digital Health Core in the Department of Psychiatry, and Director of the NIH-funded Digital Research and Interventions for Volitional Enhancement (DRIVE) lab. The goal of her research program is to design, develop, and investigate neuroscience-informed digital health solutions to improve the lives of people with schizophrenia and depression. She has a broad background in clinical psychology, with specific training in behavioral neuroscience, early detection and intervention of psychosis, and digital health research. Dr. Schlosser's research is focused on translating the latest findings in the area of reward processing and psychological determinants of motivation into new interventions to treat individuals with schizophrenia and depression. Her focus in on targeting domains that transcend diagnostic labels, such as motivational states and enhancing outcomes, such as quality of life. More recently, with funding from NIMH, her research was focused on developing a mobile app called PRIME, which was designed to target the motivational system and thereby enhance the drive to improve one's quality of life and health outcomes. Her lab is testing the feasibility and impact of PRIME in two ongoing clinical trials in schizophrenia and they recently completed a pilot trial in depression. Two of the three trials were conducted entirely remotely, one with individuals with depression and the other with individuals recently diagnosed with schizophrenia.


    Collapse Research 
    Collapse Research Activities and Funding
    Scaling a smarter and more efficient intervention: Evaluating the feasibility of disseminating a novel mobile app platform to treat depression
    NIH/NIMH R34MH110583Aug 1, 2016 - Jun 30, 2019
    Role: Principal Investigator
    Enhancing Functional Outcomes in Schizophrenia Using a Novel mHealth Approach
    NIH/NIMH R34MH100399Aug 1, 2013 - May 31, 2016
    Role: Co-Principal Investigator
    PRIME to Action: Enhancing Motivation in Recent Onset Schizophrenia
    NIH/NIMH K23MH097795May 3, 2013 - Apr 30, 2018
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Clinical Trials
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Baumel A, Baker J, Birnbaum ML, Christensen H, De Choudhury M, Mohr DC, Muench F, Schlosser D, Titov N, Kane JM. Summary of Key Issues Raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) Meeting. Psychiatr Serv. 2018 Jan 16; appips201700270. PMID: 29334875.
      View in: PubMed
    2. Campellone TR, Truong B, Gard D, Schlosser D. Social motivation in people with recent-onset schizophrenia spectrum disorders. J Psychiatr Res. 2018 Apr; 99:96-103. PMID: 29428842.
      View in: PubMed
    3. Biagianti B, Quraishi SH, Schlosser D. Potential Benefits of Incorporating Peer-to-Peer Interactions Into Digital Interventions for Psychotic Disorders: A Systematic Review. Psychiatr Serv. 2018 Apr 01; 69(4):377-388. PMID: 29241435.
      View in: PubMed
    4. Schlosser D, Campellone TR, Truong B, Anguera JA, Vergani S, Vinogradov S, Arean P. The feasibility, acceptability, and outcomes of PRIME-D: A novel mobile intervention treatment for depression. Depress Anxiety. 2017 06; 34(6):546-554. PMID: 28419621.
      View in: PubMed
    5. Biagianti B, Schlosser D, Nahum M, Woolley J, Vinogradov S. Creating Live Interactions to Mitigate Barriers (CLIMB): A Mobile Intervention to Improve Social Functioning in People With Chronic Psychotic Disorders. JMIR Ment Health. 2016 Dec 13; 3(4):e52. PMID: 27965190.
      View in: PubMed
    6. Schlosser D, Campellone T, Kim D, Truong B, Vergani S, Ward C, Vinogradov S. Feasibility of PRIME: A Cognitive Neuroscience-Informed Mobile App Intervention to Enhance Motivated Behavior and Improve Quality of Life in Recent Onset Schizophrenia. JMIR Res Protoc. 2016 Apr 28; 5(2):e77. PMID: 27125771; PMCID: PMC4865654.
      View in: PubMed, PubMed Central
    7. Loewy R, Fisher M, Schlosser D, Biagianti B, Stuart B, Mathalon DH, Vinogradov S. Intensive Auditory Cognitive Training Improves Verbal Memory in Adolescents and Young Adults at Clinical High Risk for Psychosis. Schizophr Bull. 2016 Jul; 42 Suppl 1:S118-26. PMID: 26903238; PMCID: PMC4960436 [Available on 07/01/17].
      View in: PubMed, PubMed Central
    8. Schlosser D, Campellone TR, Biagianti B, Delucchi KL, Gard DE, Fulford D, Stuart BK, Fisher M, Loewy RL, Vinogradov S. Modeling the role of negative symptoms in determining social functioning in individuals at clinical high risk of psychosis. Schizophr Res. 2015 Dec; 169(1-3):204-208. PMID: 26530628.
      View in: PubMed
    9. Schlosser D, Fisher M, Gard D, Fulford D, Loewy RL, Vinogradov S. Motivational deficits in individuals at-risk for psychosis and across the course of schizophrenia. Schizophr Res. 2014 Sep; 158(1-3):52-7. PMID: 25008792; PMCID: PMC4152418.
      View in: PubMed, PubMed Central
    10. David J. Miklowitz, Mary P. O’Brien, Danielle A. Schlosser, Jean Addington, Kristin A. Candan, Catherine Marshall, Isabel Domingues, Barbara C. Walsh, Jamie L. Zinberg, Sandra D. De Silva, Michelle Friedman-Yakoobian, Tyrone D. Cannon . Family-Focused Treatment for Adolescents and Young Adults at High Risk for Psychosis: Results of a Randomized Trial. Journal of the American Academy of Child & Adolescent Psychiatry. 2014.
    11. Miklowitz DJ, O'Brien MP, Schlosser D, Addington J, Candan KA, Marshall C, Domingues I, Walsh BC, Zinberg JL, De Silva SD, Friedman-Yakoobian M, Cannon TD. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry. 2014 Aug; 53(8):848-58. PMID: 25062592; PMCID: PMC4112074.
      View in: PubMed, PubMed Central
    12. Schlosser D. In people with ultra high risk symptoms, risk of transition to psychotic disorders is highest in the first 2 years. Evid Based Ment Health. 2014 May; 17(2):39. PMID: 24591545; PMCID: PMC4334583.
      View in: PubMed, PubMed Central
    13. Fisher M, Loewy R, Carter C, Lee A, Ragland JD, Niendam T, Schlosser D, Pham L, Miskovich T, Vinogradov S. Neuroplasticity-based auditory training via laptop computer improves cognition in young individuals with recent onset schizophrenia. Schizophr Bull. 2015 Jan; 41(1):250-8. PMID: 24444862; PMCID: PMC4266283.
      View in: PubMed, PubMed Central
    14. Fisher M, Loewy R, Hardy K, Schlosser D, Vinogradov S. Cognitive interventions targeting brain plasticity in the prodromal and early phases of schizophrenia. Annu Rev Clin Psychol. 2013; 9:435-63. PMID: 23297786; PMCID: PMC4745413.
      View in: PubMed, PubMed Central
    15. Schlosser D, Pearson R, Perez VB, Loewy RL. Environmental Risk and Protective Factors and Their Influence on the Emergence of Psychosis. Adolesc Psychiatry (Hilversum). 2012 Apr; 2(2):163-171. PMID: 23125956.
      View in: PubMed
    16. Schlosser D, Miklowitz DJ, O'Brien MP, De Silva SD, Zinberg JL, Cannon TD. A randomized trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Interv Psychiatry. 2012 Aug; 6(3):283-91. PMID: 22182667; PMCID: PMC4106700.
      View in: PubMed, PubMed Central
    17. Schlosser D, Jacobson S, Chen Q, Sugar CA, Niendam TA, Li G, Bearden CE, Cannon TD. Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis. Schizophr Bull. 2012 Nov; 38(6):1225-33. PMID: 21825282; PMCID: PMC3494042.
      View in: PubMed, PubMed Central
    18. Schlosser D, Zinberg JL, Loewy RL, Casey-Cannon S, O'Brien MP, Bearden CE, Vinogradov S, Cannon TD. Predicting the longitudinal effects of the family environment on prodromal symptoms and functioning in patients at-risk for psychosis. Schizophr Res. 2010 May; 118(1-3):69-75. PMID: 20171848; PMCID: PMC2856759.
      View in: PubMed, PubMed Central
    19. Stuart BK, Schlosser D. Multifamily group treatment for schizophrenia. Int J Group Psychother. 2009 Jul; 59(3):435-40. PMID: 19548790; PMCID: PMC3397389.
      View in: PubMed, PubMed Central
    Danielle's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (59) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (8) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    Back to TOP